Introduction
What haemophilia could learn from the sickle cell work in the International Cochrane Collaboration
Haemophilia - paucity of evidence, ways forward?
Specialised services commissioning and primary care trusts
The incidence of inhibitor development according to specific mutations - and treatment?
Management of acquired haemophilia A - more questions than answers
Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors
Catalytic antibodies to factor VIII in haemophilia A
Analysis and results of the recombinant factor VIIa extended-use registry
Update on Novo Nordisk's clinical trial programme on NovoSeven®
New insights into haemostasis in liver failure
Factor VII deficiency
Four factor deficiency
Factor XI deficiency - from molecular genetics to clinical management
vCJD screening and its implications for transfusion - strategies for the future?
Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction